Bloomberg News

German Panel Saw Little to No Added Benefit for Pfizer’s Eliquis

March 15, 2012

Pfizer Inc. (PFE) and Bristol-Myers Squibb Co. (BMY)’s Eliquis offered little to no added benefit for patients who had undergone elective hip or knee replacement surgery when compared to Sanofi’s Lovenox, a German health agency said today.

The Institute for Quality and Efficiency in Health Care, otherwise known as IQWiG, said the newer medicine offered no added benefit for prevention of venous thromboembolic events in knee surgery patients. Eliquis, known chemically as apixaban, offered a low additional benefit for hip surgery patients, the agency said in a statement posted on its website today.

To contact the editor responsible for this story: Naomi Kresge at

The Good Business Issue
blog comments powered by Disqus